68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

NO_LONGER_AVAILABLE

Conditions studied: Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors

In brief

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Key facts

Study ID
NCT01980732
Run by
Andrei Iagaru
Last updated by the study team
2017-08-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.